The Global Biopharmaceutical Cmo And Cro Market Growth Accelerated By Outsourcing Of Bioprocessing Needs
![]() |
| Biopharmaceutical CMO and CRO Marke |
The biopharmaceutical contract manufacturing (CMO) and contract research organizations (CRO) provide services for manufacturing biologics, vaccines, monoclonal antibodies, gene therapies and other therapeutics for biopharmaceutical companies. The biopharmaceutical companies outsource their needs for cell line development, protein expression and purification for efficient development and manufacturing of biotherapeutics.
The global Biopharmaceutical
CMO and CRO Market is estimated to be valued at US$ 41.71 Mn in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2023 to 2031, as highlighted in a new report
published by Coherent Market Insights.
Market key trends:
The outsourcing trend among the biopharmaceutical companies is a major driver
of growth in the biopharmaceutical CMO and CRO market. As biotherapeutic
development involves complex bioprocessing steps, many smaller biopharma
companies lack required infrastructure and expertise for activities like
mammalian cell culture, purification and downstream processing. Larger
biopharma companies also find it more cost-effective to outsource non-core
activities to contract service providers. The CMOs and CROs provide flexible,
scalable solutions tailored to client's development and manufacturing needs. This
enables biopharma companies to focus on drug discovery and clinical development
while ensuring timely supply of biologics.
Segment Analysis
The biopharmaceutical CMO and CRO market is segmented on the basis of end user,
type and service. The service segment dominates the market as CMOs and CROs
offer various services to biopharma companies such as clinical trial services,
consulting services, manufacturing services, and non-clinical services.
Clinical trial services acquire the major share under service segment owing to
increasing clinical trials for biologics and biosimilars every year.
Key Takeaways
The global Biopharmaceutical
CMO And CRO Market Size is expected to witness high growth during the
forecast period of 2023 to 2031. The
global biopharmaceutical CMO and CRO Market is estimated to be valued at US$ 41.71 Mn in 2023
and is expected to exhibit a CAGR of
5.0% over the forecast period 2023 to 2031.
Regional analysis shows that
North America dominates the market and is expected to continue its dominance
during the forecast period. This is due to presence of well-established CMOs,
CROs and biopharma companies in countries like US and Canada. Asia Pacific is
expected to be the fastest growing region mainly due to increasing investment
by governments and companies in pharmaceutical and biotechnology sector.
Key players operating in the biopharmaceutical CMO and CRO market are Albemarle
Corporation, Greenchemicals S.r.l., ICL, Jordan Bromine Company, Kingboard
Holdings Limited, LANXESS, Novel Chem, Shandong Brother Sci. & Tech. Co.,
Ltd., Shandong Futong Chemical Co., Ltd. and Tianjin Changlu Hangu Saltern Co.,
Ltd. Albemarle Corporation acquires majority share and is expanding its
manufacturing and service capabilities globally through acquisitions and collaborations
to strengthen its leadership position in the market.
Explore more related article on this topic: https://www.pressreleasebulletin.com/expanding-pharmaceutical-contract-manufacturing-capabilities-is-driven-by-increasing-drug-pipelines/
https://blogger-veritas.blogspot.com/2024/01/the-global-ventricular-assist-devices.html

Comments
Post a Comment